Vimarsana
Biggest News Aggregation in the World

Dose Combination News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Dose Combination. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Dose Combination Today - Breaking & Trending Today

Government Bans 14 Fixed-Dose Combination Drugs - Vimarsana News

Government Bans 14 Fixed-Dose Combination Drugs

Government bans 14 FDC drugs citing safety concerns and lack of therapeutic justification.

Why govt has banned 14 drugs including some paracetamol combination meds - Vimarsana News

Why govt has banned 14 drugs including some paracetamol combination meds

The Health Ministry reannounced the ban after it was challenged by pharmaceutical companies in court, based on an expert committee’s recommendations.

Govt Bans 14 Fixed-Dose Combination Drugs Including Paracetamol And Nimesulide; Check Full List Here - Vimarsana News

Govt Bans 14 Fixed-Dose Combination Drugs Including Paracetamol And Nimesulide; Check Full List Here

In a notification issued, the Union Health Ministry there is

Source: india.com
Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India - Vimarsana News

Glenmark becomes the First Pharmaceutical Company to launch Teneligliptin Pioglitazone Fixed-Dose Combination Drug for Type 2 Diabetes in India

Glenmark Pharmaceuticals Limited (Glenmark), an innovation-driven global pharmaceutical company has launched a novel fixed-dose combination (FDC) of a widely us

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs - Vimarsana News

ViiV Healthcare presents three-year switch data for Dovato (dolutegravir/lamivudine) confirming long-term, non-inferior efficacy with no virologic failure versus continuation of TAF-based regimens of at least three drugs

The Phase III TANGO study is the third trial to provide long-term evidence for Dovato, reinforcing its use as a viable switch option for people living with HIV For media and investors only ViiV